Core Viewpoint - Huakang Co., Ltd. experienced a decline of 1.06% on December 30, with a stock price of 14.92 yuan per share and a total market capitalization of 4.522 billion yuan [1] Company Overview - Zhejiang Huakang Pharmaceutical Co., Ltd. was established on July 10, 2001, and went public on February 9, 2021. The company specializes in the research, production, and sales of various functional sugar alcohols and starch sugar products, including xylitol, sorbitol, maltitol, and fructose syrup [1] - The revenue composition of the company is as follows: crystalline sugar alcohol products account for 54.36%, liquid sugars and alcohols for 32.46%, and other products for 13.18% [1] Shareholder Information - Huaxia Fund has a presence among the top ten circulating shareholders of Huakang Co., Ltd. The Huaxia Excellent Growth Mixed A Fund (024928) entered the top ten shareholders in the third quarter, holding 4.1533 million shares, which represents 1.39% of the circulating shares [2] - The estimated floating loss for the fund today is approximately 664,500 yuan [2][5] Fund Performance - The Huaxia Excellent Growth Mixed A Fund (024928) was established on August 12, 2025, with a current scale of 956 million yuan and a cumulative return of 16.17% since inception [3] - The fund manager, Zhong Shuai, has been in position for 5 years and 157 days, managing assets totaling 13.26 billion yuan. The best fund return during his tenure is 184.12%, while the worst return is -0.15% [4]

| 证券代码：605077 | 证券简称：华康股份 公告编号：2025-099 | | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | 关于实际控制人及其一致行动人减持可转换公司债券 暨权益变动的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 2024 年 10 月 1 日至 2025 年 12 月 25 日，公司实际控制人陈德水、余建 明、程新平、徐小荣及其控制的开化金悦投资管理有限公司（以下简称"开化金 悦"）因减持浙江华康药业股份有限公司（以下简称"公司"）可转换公司债券 （以下简称"可转债"）导致公司实际控制人及其控制的开化金悦拥有公司合并 权益比例变动 1.61%，合并权益比例由 30.58%下降至 28.97%。本次权益变动系可 转债减持，不触及要约收购。 本次权益变动不会导致公司实际控制人发生变化。 自 2024 年 7 月 1 日至 2025 年 12 月 25 日，陈德水、余建明、程新平、 徐小荣及其控制的开化金悦通过上海证券交易所系统合计减持 ...

Group 1 - The core viewpoint of the news is that the liquor stocks experienced a rebound on December 25, with the China Securities Food and Beverage Index rising by 0.80% in the afternoon, driven by strong performances from stocks like Shui Jing Fang, Jin Da Wei, and Jiu Gui Jiu [1] - The Tianhong Food and Beverage ETF (159736) saw significant trading activity, with a transaction volume exceeding 14 million yuan, indicating investor interest in high-end liquor stocks and related sectors [1] - A new national food safety standard will be implemented on March 16, 2027, requiring the labeling of saturated fats and sugars on pre-packaged food products, which could impact consumer purchasing behavior in the food and beverage sector [1] Group 2 - According to Galaxy Securities, the food and beverage index experienced a slight pullback in December, attributed to the timing of the Mid-Autumn Festival affecting sales data and potential revenue pressures in Q4 due to the late Spring Festival stocking period [2] - Within the sector, snacks, condiments, and pre-packaged food indices achieved small positive returns, suggesting some resilience in these sub-segments despite overall market challenges [2] - The outlook for 2026 remains optimistic for new consumption trends, with expectations of internal rotation, while traditional consumption is anticipated to show signs of bottoming out [2]

Group 1: Livestock Industry - The pig industry is currently in a phase of deep losses, with supply contraction expected to continue into the first half of 2026, leading to a significant reduction in production capacity. The average pig price for 2025 is projected to be below the cost line, with quarterly estimates of 15.5 CNY/kg, 13.5 CNY/kg, 16.4 CNY/kg, and 17.7 CNY/kg, resulting in an annual average of approximately 13.4 CNY/kg [11][25][26] - The white chicken market is experiencing a cautious outlook, with a projected supply growth of less than 5% for 2026. The decline in the sales of commodity broiler chicks indicates a more conservative price expectation within the industry [30][35] - The yellow chicken sector remains stable, with production capacity not significantly affected. The prices are expected to follow trends in other protein sources, with a focus on seasonal price increases [39] - The beef market is anticipated to see a price increase due to a clear reduction in both domestic and international supply. The wholesale price of beef has been rising, reaching 66.21 CNY/kg in December, reflecting a year-on-year increase of 9.1% [42][70] Group 2: Agricultural Inputs and Other Sectors - The feed industry is showing signs of recovery, with a 6.6% year-on-year increase in feed production for the first three quarters of 2025, indicating improved demand from the livestock sector [71][76] - The edible mushroom sector is witnessing a rebound, particularly with the reversal of the predicament faced by enoki mushrooms and the potential growth of new products like Cordyceps [3][80] - The pet industry continues to thrive, with a notable trend towards high-end domestic products, as evidenced by the performance of brands like Guibao Pet and Zhongchong Co. [4][63] - The natural sweetener market is expected to grow as consumer awareness of sugar reduction increases, with companies like Bailong Chuangyuan and Baolingbao positioned to benefit from this trend [4][71]

国浩律师（杭州）事务所 专项核查意见 国浩律师（杭州）事务所 关 于 浙江华康药业股份有限公司 终止发行股份及支付现金购买资产暨关联交易 的相关股票买卖情况之专项核查意见 1 致：浙江华康药业股份有限公司 国浩律师（杭州）事务所接受浙江华康药业股份有限公司（以下简称"华康 股份"、"公司"、"上市公司"）的委托，担任其发行股份及支付现金购买资 产暨关联交易（以下简称"本次交易"）的专项法律顾问。 公司于 2025 年 11 月 28 日召开第六届董事会第三十四次会议，审议通过了 《关于终止发行股份及支付现金购买资产暨关联交易事项并撤回申请文件的议 案》《关于公司与交易对方签署相关终止协议的议案》，同意公司终止本次交易， 并撤回申请文件，以及与交易对方签署相关终止协议。 根据《中华人民共和国证券法》《上市公司重大资产重组管理办法》《监管 规则适用指引--上市类第 1 号》等有关法律、行政法规及规范性文件的规定，本 所对本次交易的重组报告书披露之日(即 2025 年 3 月 28 日)起至华康股份披露终 止本次交易之日(即 2025 年 11 月 29 日)期间(以下称"核查期间")相关主体买 卖华康股份股票的情 ...

东方证券股份有限公司 关于浙江华康药业股份有限公司终止发行股份及支付现金 购买资产暨关联交易相关主体买卖股票情况 自查报告的核查意见 浙江华康药业股份有限公司（以下简称"华康股份"或"上市公司"或"公 司"）拟通过发行股份及支付现金，购买张其宾、谭瑞清、汤阴县豫鑫有限责任 公司、谭精忠合计持有的河南豫鑫糖醇有限公司（以下简称"豫鑫糖醇"或"标 的公司"）100%股权（以下简称"本次交易"）。 公司于 2025 年 11 月 28 日召开第六届董事会第三十四次会议， 审议通过了 《关于终止发行股份及支付现金购买资产暨关联交易事项并撤回申请文件的议案》 《关于公司与交易对方签署相关终止协议的议案》，经公司审慎研究，并与相关 交易方友好协商，同意公司终止本次交易，并撤回申请文件，以及与交易对方签 署相关终止协议。 根据《中华人民共和国证券法》《上市公司重大资产重组管理办法》《上市 公司监管指引第 7 号——上市公司重大资产重组相关股票异常交易监管》《公开 发行证券的公司信息披露内容与格式准则第 26 号——上市公司重大资产重组》 《监管规则适用指引——上市类第 1 号》及《上海证券交易所上市公司自律监管 指引第 6 ...

| 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-098 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 浙江华康药业股份有限公司 关于终止发行股份及支付现金购买资产暨关联交易 相关主体买卖股票情况自查报告的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华康药业股份有限公司（以下简称"华康股份"或"上市公司"或"公 司"）拟通过发行股份及支付现金相结合，购买张其宾、谭瑞清、汤阴县豫鑫有 限责任公司、谭精忠合计持有的河南豫鑫糖醇有限公司（以下简称"豫鑫糖醇" 或"标的公司"）100%股权（以下简称"本次交易"）。 公司于 2025 年 11 月 28 日召开第六届董事会第三十四次会议，审议通过了 《关于终止发行股份及支付现金购买资产暨关联交易事项并撤回申请文件的议案》 《关于公司与交易对方签署相关终止协议的议案》，经公司审慎研究，并与相关 交易方友好协商，同意公司终止本次交易，并撤回申请文件，以及与交易对方签 署相关终止协议。 根 ...

Group 1 - The company announced that it will terminate the issuance of shares and cash payment for the acquisition of 100% equity in Henan Yuxin Sugar Alcohol Co., Ltd. [1] - The board meeting is scheduled for November 28, 2025, to review and approve the termination of the acquisition proposal and withdraw related application documents [1] - During the self-examination period from March 28, 2025, to November 29, 2025, some individuals and institutions traded the company's stock, but the investigation confirmed that these actions did not constitute insider trading [1]

| 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-097 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 浙江华康药业股份有限公司 关于"华康转债"2025 年付息公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 浙江华康药业股份有限公司（以下简称"公司"）于 2023 年 12 月 25 日发行 的可转换公司债券将于 2025 年 12 月 25 日开始支付自 2024 年 12 月 25 日至 2025 年 12 月 24 日期间的利息。根据本公司《可转换公司债券募集说明书》有关条款 的规定，现将有关事项公告如下： 一、可转债发行上市概况 1、债券名称：浙江华康药业股份有限公司可转换公司债券 2、债券简称：华康转债 3、债券代码：111018 4、证券类型：可转换为公司 A 股股票的可转换公司债券 5、发行数量及规模：130,302.30 万元（13,030,230 张，1,303,023 手） 6、面值和发行价格： ...

一、行业概述 山梨醇（Sorbitol/山梨糖醇）是一种六元糖醇，化学式为C₆H₁₄O₆，由葡萄糖的醛基还原为羟基形成， 属于多元醇类化合物。天然存在于梨、桃、苹果、葡萄等水果及蘑菇、海带、菠菜等蔬菜中，也可通过 化学合成（如葡萄糖催化氢化、电解氧化法）或生物发酵法制备。 山梨醇化学性质 二、行业产业链 内容概况：中国山梨醇行业现处于成熟发展期，兼具规模优势与技术竞争力。2024年，中国山梨醇行业 市场规模约为75.36亿元，同比增长6.92%。这一扩张态势主要得益于健康消费趋势的强力驱动——下游 应用场景随消费者健康需求升级持续扩容。具体而言，在食品领域，山梨醇作为低热量甜味剂与保湿剂 的功能属性被深度挖掘，其添加量在饮料、烘焙制品及乳制品中呈刚性增长；医药领域则依托其作为辅 料及治疗载体的稳定性能，需求保持稳健上行；日化领域更因其在护肤品、牙膏中作为保湿剂与增稠剂 的高渗透特性，成为推动行业扩容的关键增量市场。 相关上市企业：华康股份（605077） 相关企业：山东南山铝业股份有限公司、武汉普世达生物科技有限公司、中粮糖业控股股份有限公司、 北控水务集团有限公司、江苏恒瑞医药股份有限公司、中国石油化工股份 ...